Author Correction: MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure (Scientific Reports, (2017), 7, 1, (40696), 10.1038/srep40696);MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Beaumont, Javier ^a,b   López, Begoña ^a,b   Ravassa, Susana ^a,b   Hermida, Nerea ^c   José, Gorka San ^a,b   Gallego, Idoia ^a,b   Valencia, Félix ^d   Gómez Doblas, Juan José ^d   De Teresa, Eduardo ^d   Díez, Javier ^a,b,e   González, Arantxa ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; MICRORNA; MIRN19 MICRORNA, HUMAN; TRANSCRIPTOME;

AGED; AORTIC VALVE STENOSIS; BLOOD; CARDIAC MUSCLE; COMORBIDITY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; HEART FUNCTION TEST; HUMAN; MALE; METABOLISM; RNA INTERFERENCE;

AGED; AORTIC VALVE STENOSIS; BIOMARKERS; COLLAGEN; COMORBIDITY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; GENE EXPRESSION REGULATION; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; MALE; MICRORNAS; MYOCARDIUM; RNA INTERFERENCE; TRANSCRIPTOME;

EID: 85009913423     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-63179-1     Document Type: Erratum

References (45)

1. Nkomo, V. T. et al. Burden of valvular heart diseases: a population-based study. Lancet. 368, 1005-1011 (2006).
2. Dweck, M. R., Boon, N. A. & Newby, D. E. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 60, 1854-1863 (2012).
3. Hein, S. et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 107, 984-991 (2003).
4. Weidemann, F. et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 120, 577-584 (2009).
5. Krayenbuehl, H. P., Hess, O. M., Monrad, E. S., Schneider, J., Mall, G. & Turina, M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation. 79, 744-755 (1989).
6. Golia, G. et al. Influence of myocardial fibrosis on left ventricular hypertrophy in patients with symptomatic severe aortic stenosis. Cardiology. 120, 139-145 (2011).
7. Milano, A. D. et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg. 144, 830-837 (2012).
8. Azevedo, C. F. et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 56, 278-287 (2010).
9. Robins, S. P. Biochemistry and functional significance of collagen cross-linking. Biochem Soc Trans. 35, 849-852 (2007).
10. Kasner, M. et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol. 57, 977-985 (2011).
11. López, B. et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension. 53, 236-242 (2009).
12. López, B., Querejeta, R., González, A., Larman, M. & Diez, J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension. 60, 677-683 (2012).
13. López, B. et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol. 67, 251-260 (2016).
14. López, B. et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol. 299, H1-H9 (2010).
15. Bauersachs, J. Regulation of myocardial fibrosis by MicroRNAs. J Cardiovasc Pharmacol. 56, 454-459 (2010).
16. Villar, A. V. et al. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol. 167, 2875-2881 (2013).
17. Thum, T. et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 116, 258-267 (2007).
18. Matkovich, S. J. et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation. 119, 1263-1271 (2009).
19. van Rooij, E. et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105, 13027-13032 (2008).
20. van Almen, G. C. et al. MicroRNA-18 and-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 10, 769-779 (2011).
21. Karakikes, I. et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc. 2, e000078 (2013).
22. Matkovich, S. J. et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res. 106, 166-175 (2009).
23. Ikeda, S. et al. Altered microRNA expression in human heart disease. Physiol Genomics. 31, 367-373 (2007).
24. Dawson, K. et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 127, 1466-1475 (2013).
25. Corsten, M. F. et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 3, 499-506 (2010).
26. Beaumont, J. et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin Sci. 126, 497-506 (2014).
27. Adam, O. et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 107, 278 (2012).
28. López, B. et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res. 99, 111-120 (2013).
29. Lavall, D. et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 289, 6656-6668 (2014).
30. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature. 435, 828-833 (2005).
31. Iaconetti, C. et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol. 107, 296 (2012).
32. Bonauer, A. et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 324, 1710-1713 (2009).
33. Chen, J. et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res. 112, 1557-1566 (2013).
34. Dakhlallah, D. et al. Epigenetic regulation of miR-17∼92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med. 187, 397-405 (2013).
35. Tanzer, A. & Stadler, P. F. Molecular evolution of a microRNA cluster. J Mol Biol. 339, 327-335 (2004).
36. López, B., González, A. & Díez, J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 121, 1645-1654 (2010).
37. Duisters, R. F. et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res. 104, 170-178 (2009).
38. Villar, A. V. et al. Myocardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart. 97, 1132-1137 (2011).
39. Hou, Y. et al. β-adrenoceptor regulates miRNA expression in rat heart. Med Sci Monit. 18, BR309-314 (2012).
40. López, B., González, A., Querejeta, R., Larman, M. & Diez, J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 48, 89-96 (2006).
41. Thum, T. et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 456, 980-984 (2008).
42. Tijsen, A. J. et al. The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res. 104, 61-71 (2014).
43. Pan, Z. et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β 1 pathway. Circulation. 126, 840-850 (2012).
44. Ho, K. K., Pinsky, J. L., Kannel, W. B. & Levy, D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 22, 6A-13A (1993).
45. Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 37, 2129-2200 (2016).